Clinical trial · Interventional
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
A Phase 1, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
NCT07195916CI-TRIAL-00120889recruitingPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 16, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260916-000001
Summary
Brief summary (as posted)
A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematologic Malignancies | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
| Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| INCA036873 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Part 1a Dose Escalation
- description
- INCA036873 will be administered at the protocol defined dose.
- interventionNames
- Drug: INCA036873
- type
- EXPERIMENTAL
- label
- Part 1b Dose Expansion
- description
- INCA036873 will be administered at the protocol defined dose.
- interventionNames
- Drug: INCA036873
- type
- EXPERIMENTAL
- label
- Part 1c Pharmacodynamic Cohort
- description
- INCA036873 will be administered at the protocol defined dose.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥18 years. * ECOG performance status of 0 or 1. * Histologically confirmed: * Clear cell renal cell carcinoma (ccRCC). * Diffuse large B-cell lymphoma (DLBCL, NOS). * High-grade B-cell lymphoma (HGBCL). * Peripheral T-cell lymphoma (PTCL, incl. NOS and ALCL). * Cutaneous T-cell lymphoma (CTCL, incl. MF or SS ≥Stage IIB with B0/B1 blood involvement). * Disease progression, relapse, or refractory to prior therapy: * ccRCC: ≥1 prior line incl. ICI + TKI. * DLBCL/HGBCL: ≥2 prior lines incl. immunochemotherapy and salvage. * PTCL/CTCL: ≥1 prior systemic therapy. * Measurable disease by RECIST v1.1 (ccRCC), Lugano 2014 (lymphomas), or ISCL/USCLC/EORTC (CTCL). * Tumor tissue available for central testing. Exclusion Criteria: * Untreated or progressive CNS disease unless previously treated and stable. * Other active invasive malignancy within 2 years (except certain low-risk cancers). * Prior CD70-targeting therapy, including CAR T. * ASCT or CAR T ≤12 weeks before enrollment; prior organ or allogeneic transplant. * Unresolved ≥Grade 2 toxicity from prior therapy (with exceptions). * Primary immunodeficiency or active autoimmune disease requiring immunosuppression. * Active HBV, HCV, HIV, or other chronic infections requiring systemic therapy. * Pregnancy, breastfeeding, or unwillingness to use effective contraception. Other protocol-defined Inclusion/Exclusion Criteria may apply.
References
Publications (0)
Data not yet available
No reference posted for this study.